NEPHROS, INC. (NEPH) Scorecard
- 2026-Q2: Total return Win; Revenue growth Win; EPS growth Lose.
- 2026-Q1: Total return Lose; Revenue growth Win; EPS growth Lose.
- 2025-Q4: Total return Win; Revenue growth Win; EPS growth Win.
- 2025-Q3: Total return Win; Revenue growth Win; EPS growth Lose.
50/120
All 120 Win/Lose results shown below
Every strict quarterly win earns 1 point. A loss, tie, or unavailable scoring value earns 0.
Trailing 1 year (4 quarters): 8 wins, 4 lossesLast fetched: 4 Sept 2026
Complete point ledger
Each cell identifies the missing side explicitly.
| Quarter | Total return | Revenue growth | EPS growth |
|---|---|---|---|
| 2026-Q22/3 |
WinNEPH / S&P 19.80% / 15.20% |
WinNEPH / S&P 24.20% / 15.00% |
LoseNEPH / S&P 23.08% / 50.40% |
| 2026-Q11/3 |
LoseNEPH / S&P -38.93% / -4.33% |
WinNEPH / S&P 23.25% / 11.30% |
LoseNEPH / S&P -12.50% / 27.70% |
| 2025-Q43/3 |
WinNEPH / S&P 3.17% / 2.65% |
WinNEPH / S&P 32.67% / 9.00% |
WinNEPH / S&P 1000.00% / 13.40% |
| 2025-Q32/3 |
WinNEPH / S&P 15.65% / 8.12% |
WinNEPH / S&P 32.36% / 4.61% |
LoseNEPH / S&P -255.56% / 13.45% |
| 2025-Q22/3 |
WinNEPH / S&P 137.79% / 10.94% |
WinNEPH / S&P 21.16% / 4.83% |
LoseNEPH / S&P -200.00% / 10.63% |
| 2025-Q12/3 |
WinNEPH / S&P 17.01% / -4.27% |
WinNEPH / S&P 10.34% / 4.98% |
LoseNEPH / S&P -157.14% / 10.57% |
| 2024-Q40/3 |
LoseNEPH / S&P -14.04% / 2.41% |
LoseNEPH / S&P -0.53% / 5.25% |
LoseNEPH / S&P -106.67% / 6.15% |
| 2024-Q30/3 |
LoseNEPH / S&P -18.96% / 5.89% |
LoseNEPH / S&P 0.03% / 5.89% |
LoseNEPH / S&P -52.63% / 6.11% |
| 2024-Q21/3 |
LoseNEPH / S&P -3.65% / 4.28% |
WinNEPH / S&P 12.79% / 5.38% |
LoseNEPH / S&P -72.92% / 5.12% |
| 2024-Q11/3 |
LoseNEPH / S&P -36.71% / 10.56% |
WinNEPH / S&P 22.14% / 5.71% |
LoseNEPH / S&P -75.00% / 5.59% |
| 2023-Q42/3 |
WinNEPH / S&P 133.78% / 11.69% |
WinNEPH / S&P 42.72% / 6.81% |
LoseNEPH / S&P NEPH unavailable / 7.78% |
| 2023-Q31/3 |
LoseNEPH / S&P -4.52% / -3.27% |
WinNEPH / S&P 33.67% / 7.52% |
LoseNEPH / S&P NEPH unavailable / -5.03% |
| 2023-Q22/3 |
WinNEPH / S&P 44.86% / 8.74% |
WinNEPH / S&P 18.53% / 9.50% |
LoseNEPH / S&P NEPH unavailable / -8.57% |
| 2023-Q11/3 |
LoseNEPH / S&P -7.76% / 7.50% |
WinNEPH / S&P 18.51% / 10.77% |
LoseNEPH / S&P NEPH unavailable / -15.69% |
| 2022-Q41/3 |
WinNEPH / S&P 27.47% / 7.56% |
LoseNEPH / S&P -3.08% / 11.88% |
LoseNEPH / S&P NEPH unavailable / -17.99% |
| 2022-Q30/3 |
LoseNEPH / S&P -40.52% / -4.88% |
LoseNEPH / S&P 2.19% / 13.47% |
LoseNEPH / S&P NEPH unavailable / -1.41% |
| 2022-Q20/3 |
LoseNEPH / S&P -65.23% / -16.10% |
LoseNEPH / S&P 8.91% / 13.71% |
LoseNEPH / S&P NEPH unavailable / 11.04% |
| 2022-Q10/3 |
LoseNEPH / S&P -25.42% / -4.60% |
LoseNEPH / S&P 10.81% / 15.97% |
LoseNEPH / S&P NEPH unavailable / 42.23% |
| 2021-Q41/3 |
LoseNEPH / S&P -32.73% / 11.03% |
WinNEPH / S&P 20.23% / 15.00% |
LoseNEPH / S&P NEPH unavailable / 96.40% |
| 2021-Q30/3 |
LoseNEPH / S&P -13.60% / 0.58% |
LoseNEPH / S&P 5.60% / 10.77% |
LoseNEPH / S&P NEPH unavailable / 69.42% |
| 2021-Q21/3 |
WinNEPH / S&P 52.63% / 8.55% |
LoseNEPH / S&P -8.73% / 6.58% |
LoseNEPH / S&P NEPH unavailable / 51.81% |
| 2021-Q10/3 |
LoseNEPH / S&P -22.49% / 6.17% |
LoseNEPH / S&P -20.97% / -1.06% |
LoseNEPH / S&P NEPH unavailable / 7.39% |
| 2020-Q41/3 |
WinNEPH / S&P 18.67% / 12.15% |
LoseNEPH / S&P -17.16% / -3.72% |
LoseNEPH / S&P NEPH unavailable / -33.42% |
| 2020-Q31/3 |
LoseNEPH / S&P -13.83% / 8.93% |
WinNEPH / S&P 6.86% / -2.04% |
LoseNEPH / S&P NEPH unavailable / -27.10% |
| 2020-Q22/3 |
WinNEPH / S&P 33.17% / 20.54% |
WinNEPH / S&P 39.76% / -0.46% |
LoseNEPH / S&P NEPH unavailable / -27.11% |
| 2020-Q11/3 |
LoseNEPH / S&P -36.68% / -19.60% |
WinNEPH / S&P 71.44% / 3.47% |
LoseNEPH / S&P NEPH unavailable / -14.75% |
| 2019-Q42/3 |
WinNEPH / S&P 23.60% / 9.07% |
WinNEPH / S&P 81.71% / 5.36% |
LoseNEPH / S&P NEPH unavailable / 2.99% |
| 2019-Q32/3 |
WinNEPH / S&P 46.63% / 1.70% |
WinNEPH / S&P 63.44% / 5.02% |
LoseNEPH / S&P NEPH unavailable / 0.21% |
| 2019-Q22/3 |
WinNEPH / S&P 27.08% / 4.30% |
WinNEPH / S&P 62.34% / 6.64% |
LoseNEPH / S&P NEPH unavailable / 8.65% |
| 2019-Q11/3 |
LoseNEPH / S&P -15.79% / 13.65% |
WinNEPH / S&P 59.38% / 8.12% |
LoseNEPH / S&P NEPH unavailable / 14.29% |
| 2018-Q42/3 |
WinNEPH / S&P -5.00% / -13.52% |
WinNEPH / S&P 49.30% / 9.05% |
LoseNEPH / S&P NEPH unavailable / 18.23% |
| 2018-Q31/3 |
LoseNEPH / S&P -1.64% / 7.71% |
WinNEPH / S&P 65.18% / 10.21% |
LoseNEPH / S&P NEPH unavailable / 19.06% |
| 2018-Q22/3 |
WinNEPH / S&P 45.24% / 3.43% |
WinNEPH / S&P 62.35% / 9.03% |
LoseNEPH / S&P NEPH unavailable / 14.46% |
| 2018-Q11/3 |
LoseNEPH / S&P -6.67% / -0.76% |
WinNEPH / S&P 64.84% / 7.68% |
LoseNEPH / S&P NEPH unavailable / 12.46% |
| 2017-Q42/3 |
WinNEPH / S&P 50.00% / 6.64% |
WinNEPH / S&P 64.25% / 7.03% |
LoseNEPH / S&P NEPH unavailable / 13.82% |
| 2017-Q32/3 |
WinNEPH / S&P 30.43% / 4.48% |
WinNEPH / S&P 56.07% / 5.68% |
LoseNEPH / S&P NEPH unavailable / 17.57% |
| 2017-Q21/3 |
LoseNEPH / S&P -39.47% / 3.09% |
WinNEPH / S&P 45.75% / 4.83% |
LoseNEPH / S&P NEPH unavailable / 17.74% |
| 2017-Q11/3 |
LoseNEPH / S&P 2.70% / 6.07% |
WinNEPH / S&P 23.89% / 3.67% |
LoseNEPH / S&P NEPH unavailable / 13.32% |
| 2016-Q41/3 |
LoseNEPH / S&P 0.00% / 3.82% |
WinNEPH / S&P 19.41% / 2.09% |
LoseNEPH / S&P NEPH unavailable / 7.05% |
| 2016-Q32/3 |
WinNEPH / S&P 42.31% / 3.85% |
WinNEPH / S&P 17.60% / 0.20% |
LoseNEPH / S&P NEPH unavailable / -3.15% |
Dividend-reinvested, split-adjusted total return
1Y · 2025-08-29 to 2026-08-27
| Metric | NEPH total return | S&P 500 Total Return Index |
|---|---|---|
| Total return | 15.55% | 20.78% |
| Annualized return | 15.55% | 20.78% |
5Y · 2021-09-01 to 2026-08-27
| Metric | NEPH total return | S&P 500 Total Return Index |
|---|---|---|
| Total return | -49.11% | 83.14% |
| Annualized return | -12.64% | 12.86% |
10Y · 2016-09-01 to 2026-08-27
| Metric | NEPH total return | S&P 500 Total Return Index |
|---|---|---|
| Total return | -9.64% | 319.30% |
| Annualized return | -1.01% | 15.41% |
Calculation rules
- window
- Latest 40 completed benchmark quarters; unavailable issuer evidence remains visible and scores 0.
- return Basis
- Issuer adjusted close reinvests distributions and normalizes splits; the S&P 500 Total Return Index is the direct benchmark.
- point Rule
- Strict same-quarter win = 1. Loss, tie or unavailable evidence = 0. No partial or subjective points.
- frequency
- Quarter endpoints only.
- fundamentals
- Trailing-four-quarter issuer revenue and EPS growth use the issuer's normalized government-filed facts.
- non Scoring
Snapshot captured 2026-09-04.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Sensus Healthcare, Inc. (SRTS) | United States | $0.048B | -3.24 |
| SANUWAVE Health, Inc. (SNWV) | United States | $0.041B | 5.47 |
| Spectral AI, Inc. (MDAI) | United States | $0.052B | |
| Xtant Medical Holdings, Inc. (XTNT) | United States | $0.053B | |
| TELA Bio, Inc. (TELA) | United States | $0.057B | -0.82 |
| InspireMD, Inc. (NSPR) | $0.033B | ||
| PAVmed Inc. (PAVM) | United States | $0.031B | -3.00 |
| Glucotrack, Inc. (GCTK) | United States | $0.027B | |
| ACCURAY INC (ARAY) | United States | $0.027B | -0.63 |
| DarioHealth Corp. (DRIO) | $0.066B | -1.39 |